Patients with a pressure of >24 mmHg were randomized to latanoprost or travoprost for an 8-week treatment period after a 6-week medicine-free period. Patients were then switched to the opposite treatment for the second period. At untreated baseline and at the end of each treatment period the IOP was measured at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am.
Main Outcome Measure
Diurnal IOP.
Results
The mean 24-hour IOP was 25.1±2.5 mmHg at baseline, 17.8±2.1 mmHg on latanoprost, and 17.3±2.2 mmHg on travoprost (P = 0.001). Individual time points were similar between treatments, except at 6 pm when travoprost provided lower IOP (16.7±2.6 vs 17.9±2.5 mmHg, P<0.001). Adverse events showed more conjunctival hyperemia with travoprost (n = 15) than latanoprost (n = 6; P = 0.03).
Conclusions
Latanoprost and travoprost both significantly reduce the 24-hour IOP from baseline in exfoliative glaucoma, but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon.
1Glaucoma Unit, Department of Ophthalmology, A University, Thessaloniki, Greece.
2Department of Ophthalmology, Democritus University of Thrace, Alexandroupolis, Greece.
3Department of Ophthalmology, Agios Andreas Hospital, Patras, Greece.
4Pharmaceutical Research Network, LLC, Charleston, South Carolina.
5School of Medicine, University of South Carolina, Columbia, South Carolina.
Correspondence to William C. Stewart, MD, Pharmaceutical Research Network, LLC, 1 Southpark Circle, Suite 110, Charleston, SC 29407.
Manuscript no. 2006-442.
This clinical trial received no outside financial support from any public or private funding organization. None of the authors had any proprietary interest in the products mentioned in the article.
ABSTRACT